tbuckley/cabot-search huggingface dataset:
The Controversial Epidemiology of Left Ventricular Dysfunction in Patients With Myotonic Dystrophy Type 1—Reply
Authors: Tanyanan Tanawuttiwat, Gordon Tomaselli, Saman Nazarian
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Prospective comparison of coefficient attenuation parameter and ultrasound for grading graft steatosis in a large real-life cohort of liver-transplant patients
Authors: C. Stern, C. Francoz, A. Payance, P.E. Rautou, M. Ronot, V. Paradis, P. Bedossa, F. Durand, V. Vilgrain, L. Castera
Journal: Journal of Hepatology (2017)
High SVR 12 rates following treatment with direct acting antiviral agents (DAA) in a German multicentre cohort of HCV/HIV-1 coinfected patients on the transplant waiting list with advanced liver cirrhosis
Authors: J. Schwarz, C. Werner, M. Steurer, U. Spengler, H. Wedemeyer, T. von Hahn, W. Stremmel, A. Pathil-Warth, T. Berg, C. Engelmann, U. Seybold, E. Schott, U. Blessin, N. Malek, U. Lauer, C. Berg
Journal: Journal of Hepatology (2017)
Phenotypic and genotypic shifts of hepatitis B virus in treatment naïve patients following extensive use of antivirals in a chronic Hepatitis B endemic area
Authors: C.-T. Yeh, C.-W. Hsu, C.-L. Lin, K.-H. Liang, M.-W. Lai, M.-L. Chang, W.-R. Lin, Y.-C. Chen
Journal: Journal of Hepatology (2017)
Declining Incidence Rates of Prostate Cancer in the United States
Authors: Mary K. Downer, Meir J. Stampfer, Matthew R. Cooperberg
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
The circulation of specific vaccine-escape HBsAg mutations in HBV genotype D infected patients correlates with high viremia and affects HBsAg detection and quantification
Authors: R. Salpini, L. Piermatteo, D. Di Carlo, A. Battisti, L. Colagrossi, A. Bertoli, L. Fabeni, V. Fini, A. Iuvara, A. Ricciardi, C. Cerva, C. Sarrecchia, M. Lichtner, C. Mastroianni, G. De Sanctis, M. Paoloni, M. Marignani, C. Pasquazzi, N. Iapadre, T. Mari, G. Parruti, S. Romano, M. Visca, A. Moretti, J. Vecchiet, L. Sarmati, M. Andreoni, G. Cappiello, A. Spanò, S. Grelli, M. Angelico, C.F. Perno, V. Svicher
Journal: Journal of Hepatology (2017)
Perceived Discrimination Experienced by Physician Mothers and Desired Workplace Changes
Authors: Taiwo Adesoye, Christina Mangurian, Esther K. Choo, Christina Girgis, Hala Sabry-Elnaggar, Eleni Linos
Journal: JAMA Internal Medicine (2017)

Monee Rassolian, MD; Lars E. Peterson, MD, PhD; Bo Fang, PhD; H. Clifton Knight Jr, MD; Michael R. Peabody, PhD; Elizabeth G. Baxley, MD; Arch G. Mainous III, PhD
Abstract 333: Chemokine and Autophagy-Related Genes in Novel In Vivo and In Vitro Models for Viral Myocarditis
Authors: Eiichiro Kawai, Seiichi Omura, Fumitaka Sato, Nicholas E Martinez, Ganta V Chaitanya, William C Claycomb, J S Alexander, Ikuo Tsunoda
Journal: Circulation Research (2012)

Picornavirus infection is one of leading causes of myocarditis in humans. Theiler's murine encephalomyelitis virus (TMEV) belongs to the genus Cardiovirus , the family Picornaviridae . While TMEV has been used as a mouse model for multiple sclerosis (MS), TMEV can also cause myocarditis in mice. We found that the susceptibilities of mouse strains to myocarditis differed from susceptibilities to the MS model. In the heart, we detected viral replication and inflammation. However, it is unclear whether virus itself or immune cells damaged the heart. To clarify the role of direct virus infection in myocarditis we used the cardiomyocyte cell line, HL-1, which retains a differentiated cardiomyocyte phenotype and contractile activity. We infected HL-1 with TMEV and monitored cytopathic effect (CPE) and cell viability. At 8 hours post infection (hpi), HL-1 cells developed CPE with decreased contractile activities, while cell death was not obvious. We detected 54% and 93% of cell death at 12 and 24 hpi, respectively, while no cell death was observed in mock-infection. We conducted microarray analyses to compare mRNA expression patterns between TMEV and mock-infected groups, using an Affymetrix GeneChip Mouse 1.0 ST Array. Principal component analysis (PCA) for microarray data clearly separated TMEV- and mock-infected groups (PC1 proportion of variance, 59%). TMEV infection induced high expression of several interferon-associated and chemokine genes, particularly Cxcl10/IP-10 . Cxcl10 is a potent chemoattractant for activated T cells and NK cells, and its potential roles have been associated with immune cells in other myocarditis models. Our current results demonstrated that virus infection alone could induce Cxcl10 in cardiomyocytes without immune cells. We also found upregulation of autophagy-related 12 gene ( Atg12 ). In general, autophagy can contribute to eradication of intracellular pathogens including viruses. However, since induction of autophagy by picornavirus has been shown to enhance virus replication, autophagy may also play a detrimental role in TMEV-induced myocarditis. Our novel in viv o and in vitro models of myocarditis are powerful tools to dissect the role of viral and immune pathogenesis of the heart, complementing each other.
Expression of genes associated with anti-viral response in EGFR mutant non-small cell lung cancer (NSCLC)
Authors: N. Karachaliou, A. Giménez-Capitán, A. Drozdowskyj, E. Aldeguer, M. González Cao, A.F. Cardona, G. López-Vivanco, J.M. Sánchez, M.D.L.L. Gil, R. Rosell
Journal: Annals of Oncology (2017)
Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals
Authors: E.P. Mas, N. Caro-Pérez, J. Gregori, P. González, C. Bartres, M.E. Soria, C. Perales, S. Lens, Z. Mariño, G. Koutsoudakis, J. Quer, X. Forns, S. Pérez-del-Pulgar
Journal: Journal of Hepatology (2017)
Influence of host characteristics and pharmacological properties on type of liver injury in hepatotoxicity
Authors: A. Gonzalez-Jimenez, M. Chen, K. McEuen, C. Stephens, I. Medina-Caliz, M. Robles-diaz, M. Slim, M.I. Lucena, A. Suzuki, R. Andrade
Journal: Journal of Hepatology (2017)
Afatinib vs gefitinib for treatment-naïve patients with EGFRm+ NSCLC (LUX-Lung 7): Analysis of time to treatment failure and impact of afatinib dose adjustment
Authors: J.C.-H. Yang, L. Paz-Ares, E.-H. Tan, K. O'Byrne, L. Zhang, M. Boyer, T. Mok, V. Hirsh, J. Fan, K. Park
Journal: Annals of Oncology (2017)
Expression of Notch family members in stage IV renal cell carcinoma tumors: Notch1 as medium-risk prognosis factor.
Authors: Luis M. Antón Aparicio, Vanessa Medina Villaamil, Guadalupe Aparicio Gallego, Maria Quindós Varela, Sergio Vazquez-Estevez, Luis Leon Mateos, Francisco J. Afonso Afonso, Jose Luis Firvida Perez, Manuel Ramos Vazquez, Ovidio Fernández Calvo, Lucía Santomé, Martin Lázaro Quintela, Isabel Santamarina Cainzos, Urbano Anido
Journal: Journal of Clinical Oncology (2012)

e15076 Background: The characterization of factors involved in the etiology of renal cell carcinoma (RCC) may lead to the identification of new targets for therapy and prognostic markers. Recent data indicate that Notch family members can be expressed by malignant RCC cells and this expression may have potential use as a strong prognostic factor. The aim of this study was to investigate the potential of Notch family members as prognostic markers for stage IV patients. Methods: We analyzed, by means of immunohistochemistry and quantitative polymerase chain reaction, protein and mRNA levels of 4 Notch family members in tumor specimens obtained from 48 patients with stage IV RCC. Clinicopathological data for these patients were evaluated. A 34% of the population had hypertension, 7.3% had hypothyroidism, 19.5% were diabetic, 7.7% prediabetic, and 22% showed hyperlipidemia. RCC specimens included clear cell RCC: 34; papillary: 3; mixed: 1; undifferentiated: 1; hypernephroma: 1.The association among biomarkers and clinicopathological factors were explored using One-Way ANOVA test and non-parametric statistics, Mann-Whitney U and Kruskal-Wallis tests. Results: Relative expression of Nocth3 and Notch4 transcript levels were elevated 25-fold in clear cell RCC tumors when compared with normal kidney tissues. Notch1 and Notch2 were overexpressed at protein level in clear cell RCC (p&gt;0.05). Those renal tumors with right localization showed highest levels of Notch4 protein (p=0.096). Notch2 overexpression was associated with patients who had undergone nefrectomy (p=0.038). Finally, Bonferroni post-hoc statistic test showed us a statistically significant association (p = 0.020) between Nocth1 protein expression levels and patients with medium risk prognosis. Conclusions: These results show a deregulated expression of Notch receptors in RCC and suggest a role for this pathway in the progression of this tumoral pathology.
A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function
Authors: Hyun Yang, Hyun Young Woo, Soon Kyu Lee, Ji Won Han, Bohyun Jang, Hee Chul Nam, Hae Lim Lee, Sung Won Lee, Do Seon Song, Myeong Jun Song, Jung Suk Oh, Ho Jong Chun, Jeong Won Jang, Angelo Lozada, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Journal: Clinical and Molecular Hepatology (2017)

Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS.The median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (≥400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008).MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.
Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry
Authors: P. Gisondi, L. Bianchi, A. Conti, P. Dapavo, P. Malagoli, S. Piaserico, F. Savoia, F. Prignano, G. Girolomoni
Journal: British Journal of Dermatology (2017)

Infliximab is a chimeric human-murine monoclonal antibody that is very effective in chronic plaque psoriasis reaching a Psoriasis Area and Severity Index (PASI) 75 response in 80.4% of patients at week 10.1 The more common adverse events include infusion reactions and upper respiratory tract infections.2 The European Medicines Agency has approved the use of infliximab biosimilar CT-P13 for psoriasis by extrapolating efficacy from studies in rheumatoid arthritis and ankylosing spondilytis.3,4

This article is protected by copyright. All rights reserved.
Granulocyte colony-stimulating factor induces hFc gamma RI (CD64 antigen)-positive neutrophils via an effect on myeloid precursor cells
Authors: JM Kerst, JG van de Winkel, AH Evans, M de Haas, IC Slaper-Cortenbach, TP de Wit, AE von dem Borne, CE van der Schoot, RH van Oers
Journal: Blood (1993)
A randomized phase II trial of adjuvant chemotherapy with S-1 versus S-1 and gemcitabine (GS) versus gemcitabine alone (GEM) in patients with resected pancreatic cancer (CAP-002 study).
Authors: Hideyuki Yoshitomi, Hiroaki Shimizu, Hiroyuki Yoshidome, Masayuki Ohtsuka, Atsushi Kato, Katsunori Furukawa, Tsukasa Takayashiki, Satoshi Kuboki, Daiki Okamura, Daisuke Suzuki, Masayuki Nakajima, Toshiaki Aida, Masaru Miyazaki
Journal: Journal of Clinical Oncology (2013)

4056 Background: Although the adjuvant therapy using GEM is now the standard therapy for patients with resected pancreatic cancer (PC), the prognosis still remains poor. Resent study demonstrated the non-inferiority of S-1 and superiority of GS to GEM with respect to progression free survival in patients with unresectable pancreatic cancer. Methods: Patients with invasive ductal PC who underwent radical surgery were enrolled. After stratification for R0/1, stage and institution, patients were randomized to receive GEM (GEM 1g/ m 2, iv, d1, 8, and 15, q4w X12), S-1 (80/100/120mg/day based on BSA, po, d1-14, q3w X 16) or GS (S-1 60/80/100mg/day based on BSA po, d1-14 plus GEM 1g/ m 2, iv, d8, 15, q3w X 16) within 8weeks after operation. Eligibility included histological residual tumor (R) 0 or 1, and no previous chemo- or/and radiation therapy. Primary endpoint was 2y disease free survival (DFS) rate and secondary endpoints included overall survival (OS), and safety. Results: Between January 2007 and October 2010, 96 patients were randomized into the three arms of the trial (32 pts to each group). Patients’ characteristics were well balanced (GEM/S-1/GS) with regard to age (66/67/66y), tumor location (head 66/69/75%), tumor status (T3+4 88/78/91%), and nodal status (positive 75/69/75%). Until November 2012, 74 events (77%) have occurred for DFS. Two year DFS rate was 24.2%, 28.1% and 34.4% in GEM, S-1 and GS, respectively and there was no significant difference between groups. The median OS was 21m in GEM, 26m in S-1 and 27.9m in GS (Log rank test: N.S.). Grade 3/4 toxicities in GEM/S-1/GS were hematological 63/10/74% and non-hematological 17/10/23%, respectively. No treatment related death was observed during the study. Conclusions: S-1 and GS provided similar efficacy to GEM as the adjuvant chemotherapy for resected PC. According to the results, S-1 and GS is the adequate combination for phase III trial to examine the efficacy of adjuvant chemotherapy for PC. Clinical trial information: UMIN000002000.
Effectiveness and cost-effectiveness of antiviral treatment initiation in hepatitis C related decompensated cirrhosis in France
Authors: C. Willmington, N. Ganne-Carrié, F. Roudot-Thoraval, V. Leroy, H. Fontaine, V. Canva-Delcambre, D. Larrey, S. Pol, P. Mathurin, Y. Yazdanpanah, S. Deuffic-Burban
Journal: Journal of Hepatology (2017)
Role of α-ketoglutarate and β-hydroxybutyrate in morbid obesity-associated non-alcoholic fatty liver disease: metabolomic approach
Authors: N. Cabré, F. Luciano-Mateo, A. Hernández-Aguilera, S. Fernández-Arroyo, A. García-Heredia, G. Baiges-Gaya, J. Camps, J. Joven
Journal: Journal of Hepatology (2017)
Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta‐analysis
Authors: S. Dhami, U. Nurmatov, S. Arasi, T. Khan, M. Asaria, H. Zaman, Arnav Agarwal, G. Netuveli, G. Roberts, O. Pfaar, A. Muraro, I. J. Ansotegui, M. Calderon, C. Cingi, S. Durham, R. Gerth van Wijk, S. Halken, E. Hamelmann, P. Hellings, L. Jacobsen, E. Knol, D. Larenas‐Linnemann, S. Lin, P. Maggina, R. Mösges, H. Oude Elberink, G. Pajno, R. Panwankar, E. Pastorello, M. Penagos, C. Pitsios, G. Rotiroti, F. Timmermans, O. Tsilochristou, E.‐M. Varga, C. Schmidt‐Weber, J. Wilkinson, A. Williams, M. Worm, L. Zhang, A. Sheikh
Journal: Allergy (2017)

Abstract Background The European Academy of Allergy and Clinical Immunology ( EAACI ) is in the process of developing Guidelines on Allergen Immunotherapy ( AIT ) for Allergic Rhinoconjunctivitis. To inform the development of clinical recommendations, we undertook a systematic review to assess the effectiveness, cost‐effectiveness, and safety of AIT in the management of allergic rhinoconjunctivitis. Methods We searched nine international biomedical databases for published, in‐progress, and unpublished evidence. Studies were independently screened by two reviewers against predefined eligibility criteria and critically appraised using established instruments. Our primary outcomes of interest were symptom, medication, and combined symptom and medication scores. Secondary outcomes of interest included cost‐effectiveness and safety. Data were descriptively summarized and then quantitatively synthesized using random‐effects meta‐analyses. Results We identified 5960 studies of which 160 studies satisfied our eligibility criteria. There was a substantial body of evidence demonstrating significant reductions in standardized mean differences ( SMD ) of symptom ( SMD −0.53, 95% CI −0.63, −0.42), medication ( SMD −0.37, 95% CI −0.49, −0.26), and combined symptom and medication ( SMD −0.49, 95% CI −0.69, −0.30) scores while on treatment that were robust to prespecified sensitivity analyses. There was in comparison a more modest body of evidence on effectiveness post‐discontinuation of AIT , suggesting a benefit in relation to symptom scores. Conclusions AIT is effective in improving symptom, medication, and combined symptom and medication scores in patients with allergic rhinoconjunctivitis while on treatment, and there is some evidence suggesting that these benefits are maintained in relation to symptom scores after discontinuation of therapy.
EGFR mutation incidence and characteristics in non-squamous lung carcinoma in the Lebanese population.
Authors: Joseph Gergi Kattan, Fady Haddad, Hampig Raphael Kourie, Samah Naderi, Marc Rassy, Fadi Rafic El Karak, Marwan Ghosn, Claude Sader-Ghorra
Journal: Journal of Clinical Oncology (2015)

e18506 Background: EGFR represents an important target in the treatment of lung adenocarcinomas; many anti-EGFR therapies are approved as first line and second-line treatment in patients having metastatic lung adenocarcinomas. The incidence of this mutation varies in terms of race; it’s around 10% in Caucasians and can reach the 30% in Asians. This incidence has not been yet determined in the Middle East. Methods: 170 patients diagnosed with non-squamous lung carcinomas starting march 2013 were included in the study, in Hôtel-Dieu de France, a tertiary medical center in Lebanon. EFGR mutations were analyzed using real time PCR technic on Rotor-Gene Q using Scorpions and ARMS technologies. Mutation status of EGFR, age, gender, type of mutation, smoking status of the patients, histology subtype, stage and sampling method of the tumor were the variables that were analyzed using SPSS 20. Results: The mean age of the patients is 65.2 years [31-87]; 40.2% were women. 76.8% of the included patients were smokers or ex-smokers. 14.8% had a localized disease, 18.5% locally advanced and 65.1% metastatic disease. 92.1% had adenocarcinoma as a histologic subtype, 3.7 % adeno-squamous, 2.6% large cells and 1.6% non-small cell not otherwise specified. 12.7% of included lung cancers had an EGFR mutation: 50% of them presented a deletion on exon 19, 41.6% a L858R mutation on exon 21, 4.2% a G719X mutation on exon 18 and 4.2% an insertion in exon 20. Patients having EGFR mutation were more frequently women (two-third) with p < 0.05 and non-smoker (two-third) with p < 0.05. Conclusions: 12.7% incidence of EGFR mutation in Lebanese population is closer to its incidence in Caucasian compared to Asian population. Similarly, this mutation is significantly more frequent in women and non –smokers.